Xenon Pharmaceuticals Return on Investment 2012-2022 | XENE
Current and historical return on investment (ROI) values for Xenon Pharmaceuticals (XENE) over the last 10 years.
Xenon Pharmaceuticals ROI - Return on Investment Historical Data |
Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
2022-03-31 |
$-0.08B |
|
inf% |
2021-12-31 |
$-0.08B |
|
inf% |
2021-09-30 |
$-0.07B |
|
inf% |
2021-06-30 |
$-0.06B |
|
inf% |
2021-03-31 |
$-0.04B |
|
inf% |
2020-12-31 |
$-0.03B |
|
inf% |
2020-09-30 |
$-0.03B |
|
-120.39% |
2020-06-30 |
$-0.03B |
|
-63.49% |
2020-03-31 |
$-0.04B |
|
-56.14% |
2019-12-31 |
$-0.04B |
$0.10B |
-44.90% |
2019-09-30 |
$-0.04B |
$0.09B |
-39.31% |
2019-06-30 |
$-0.05B |
$0.10B |
-40.27% |
2019-03-31 |
$-0.04B |
$0.11B |
-40.68% |
2018-12-31 |
$-0.04B |
$0.12B |
-44.71% |
2018-09-30 |
$-0.04B |
$0.13B |
-57.58% |
2018-06-30 |
$-0.03B |
$0.06B |
-95.65% |
2018-03-31 |
$-0.03B |
$0.03B |
-173.68% |
2017-12-31 |
$-0.03B |
$0.04B |
-314.29% |
2017-09-30 |
$-0.03B |
|
inf% |
2017-06-30 |
$-0.03B |
|
inf% |
2017-03-31 |
$-0.03B |
|
inf% |
2016-12-31 |
$-0.02B |
|
inf% |
2016-09-30 |
$-0.02B |
|
inf% |
2016-06-30 |
$-0.02B |
|
inf% |
2016-03-31 |
$-0.01B |
|
inf% |
2015-12-31 |
$-0.01B |
|
inf% |
2015-09-30 |
$-0.01B |
|
inf% |
2015-06-30 |
$0.00B |
|
inf% |
2015-03-31 |
$0.00B |
|
inf% |
2014-12-31 |
$0.01B |
|
inf% |
2014-06-30 |
$0.01B |
|
inf% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$1.548B |
$0.018B |
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
|